These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 36844032)
1. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ Front Psychiatry; 2022; 13():1076459. PubMed ID: 36844032 [TBL] [Abstract][Full Text] [Related]
2. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898 [TBL] [Abstract][Full Text] [Related]
3. Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. Kuburi S; Di Passa AM; Tassone VK; Mahmood R; Lalovic A; Ladha KS; Dunlop K; Rizvi S; Demchenko I; Bhat V Chronic Stress (Thousand Oaks); 2022; 6():24705470221115342. PubMed ID: 35936944 [TBL] [Abstract][Full Text] [Related]
4. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Sousa TR; Rema J; Machado S; Novais F Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736 [TBL] [Abstract][Full Text] [Related]
5. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Dos Santos RG; Hallak JE; Baker G; Dursun S J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of psychedelics in psychiatry, a systematic review of the literature]. Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297 [TBL] [Abstract][Full Text] [Related]
7. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maede K; González-Maeso J; Kitagaki S; Hiramatsu M Res Sq; 2023 Jul; ():. PubMed ID: 37461593 [TBL] [Abstract][Full Text] [Related]
8. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716 [TBL] [Abstract][Full Text] [Related]
11. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Johnson MW; Hendricks PS; Barrett FS; Griffiths RR Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880 [TBL] [Abstract][Full Text] [Related]
12. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; Zhang Y; Chan AW Front Psychiatry; 2024; 15():1386321. PubMed ID: 38807690 [TBL] [Abstract][Full Text] [Related]
13. Psychedelics in the treatment of unipolar and bipolar depression. Bosch OG; Halm S; Seifritz E Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817 [TBL] [Abstract][Full Text] [Related]
14. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784 [TBL] [Abstract][Full Text] [Related]
15. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708 [TBL] [Abstract][Full Text] [Related]
16. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. Artin H; Zisook S; Ramanathan D World J Psychiatry; 2021 Jun; 11(6):201-214. PubMed ID: 34168967 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. Markopoulos A; Inserra A; De Gregorio D; Gobbi G Front Pharmacol; 2021; 12():749068. PubMed ID: 35177979 [TBL] [Abstract][Full Text] [Related]
18. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Leger RF; Unterwald EM J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Applications of Classic Hallucinogens. Bogenschutz MP; Ross S Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684 [TBL] [Abstract][Full Text] [Related]